Epic Sciences

Epic Sciences is a San Diego, California-based biotechnology company that develops clinical liquid biopsy diagnostics to detect and characterize circulating tumor cells for personalized cancer treatment. The private company utilizes a proprietary platform licensed from the Scripps Research Institute to enable the non-invasive monitoring of genetic and molecular changes in oncology patients. Epic Sciences has raised $85.5 million in total venture capital funding and processed over 10,000 patient samples to support real-time clinical decision-making. The organization provides diagnostic services and companion diagnostics for more than 200 clinical trials, partnering with 65 pharmaceutical companies and 45 academic institutions, including the National Cancer Institute. Previous executive leadership included former presidents Murali Prahalad and David Nelson, who helped establish the firm's commercialization strategy. Currently led by Chief Executive Officer Lloyd Sanders, the enterprise was founded in 2008.

High-Level Overview

Epic Sciences is a biotechnology company founded in 2008 that develops novel diagnostics to personalize and advance cancer treatment and management.[1][2][3] Its core mission is to enable rapid, non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey, using a proprietary platform to identify and characterize rare cells like circulating tumor cells (CTCs).[1][2][3][4] The company serves physicians, patients, pharmaceutical partners (over 65), and major cancer centers (including 45 academic hospitals and the National Cancer Institute), solving the problem of matching patients to targeted therapies, monitoring drug resistance, and improving clinical trial success by providing real-time insights for treatment decisions.[2][3][4] With 51-200 employees headquartered in San Diego, Epic has demonstrated growth through a $52 million Series E financing in 2018, CAP accreditation, partnerships like Genomic Health for the Oncotype DX AR-V7 Nucleus Detect test for prostate cancer, involvement in over 200 clinical trials, and testing of more than 10,000 patient samples.[1][3][4][5]

Origin Story

Epic Sciences was established in 2008 in San Diego on a foundational platform for detecting rare cells, including CTCs, to address gaps in cancer diagnostics.[1][2][3][4] While specific founders are not detailed in available sources, the company has been led by CEO Lloyd Sanders (placed via executive search), with key executives including Chief Innovation Officer Ryan Dittamore, Chief Scientific Officer Pascal Bamford, Chief Commercial Officer Katherine Atkinson, and others in research, lab, and finance roles.[1] Early traction came from building "No Cell Left Behind®" technology, securing partnerships with pharma and cancer centers, and expanding its test pipeline for cancers like prostate, breast, lung, and bladder; pivotal moments include CAP accreditation, the 2018 Series E funding, and commercialization efforts like the AR-V7 test with Genomic Health.[3][4][5]

Core Differentiators

Epic Sciences stands out in oncology diagnostics through these key strengths:

• Proprietary Rare-Cell Detection Platform: "No Cell Left Behind®" technology identifies and characterizes CTCs and immune cells without missing rare events, enabling insights into clonal evolution, drug resistance, and therapy matching across drug classes.[2][3][4]
• Comprehensive Test Pipeline: World's leading lineup of personalized, predictive tests for prostate, breast, lung, and bladder cancers, used in over 200 clinical trials and 10,000+ patient samples.[3]
• Proven Partnerships and Scale: Collaborates with 65+ pharma companies and 45+ cancer centers worldwide, including NCI, boosting clinical trial efficiency and patient outcomes.[2][3][4]
• Biopharma and Clinical Focus: Supports translational research, drug development, and real-time physician guidance, with CAP-accredited labs for reliability.[3][4][5]

Role in the Broader Tech Landscape

Epic Sciences rides the wave of precision oncology and liquid biopsy trends, where non-invasive blood tests replace invasive biopsies to track cancer dynamics in real time.[2][3][4] Timing aligns with surging demand for personalized medicine amid rising cancer prevalence and immunotherapy advancements, as market forces like high clinical trial failure rates (favoring Epic's success-boosting tools) and payer pressures for cost-effective treatments propel adoption.[3][4] By partnering globally and influencing 200+ trials, Epic shapes the ecosystem, accelerating drug approvals, reducing ineffective therapies, and enabling pharma to optimize trials while empowering physicians with data-driven decisions.[2][4]

Quick Take & Future Outlook

Epic Sciences is poised to expand its diagnostic pipeline and market presence, leveraging its platform for new tests in high-impact cancers and combination therapies amid AI-enhanced biotech integration.[2][3][4] Trends like multimodal liquid biopsies and immune monitoring will shape its path, potentially driving acquisitions or IPOs as oncology spending hits new highs. Its influence could grow by dominating predictive testing, tying back to its mission of transforming patient journeys through certainty in pivotal decisions.[1][3]